Therefore, the applicability/usefulness of CK2 inhibitors in T-ALL patients should be further investigated, as the degree of response could be dependent on IKZF1 deletion and PI3K pathway alterations. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.